comparemela.com

Latest Breaking News On - Prnewswire cantargia - Page 4 : comparemela.com

Cantargia reports first non-squamous NSCLC patient treated with nadunolimab, Keytruda® and chemotherapy

(Nasdaq: CANTA) (Stockholm: CANTA) today reported that the first patient has been treated in a new arm of.

Prnewswire cantargiaNasdaq stockholm

Cantargia AB: Cantargia: Oral presentation of new preclinical CAN10 efficacy data in systemic sclerosis at ACR Convergence

LUND, Sweden, Sept. 15, 2022 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported new preclinical data demonstrating efficacy of its anti-inflammatory IL1RAP-binding

United statesPrnewswire cantargiaHeinrich heine university hiller research centerNasdaq stockholmSystemic sclerosisRelated disorders

Cantargia AB: Cantargia presents preclinical data demonstrating unique treatment effects of nadunolimab on pancreatic cancer stromal cells

LUND, Sweden, Sept. 14, 2022 /PRNewswire/ Cantargia (Cantargia AB) (NASDAQ Stockholm: CANTA) today reported preclinical data for its lead candidate, the IL1RAP-binding antibody nadunolimab

United statesPrnewswire cantargiaLund universityPancreatic cancer action network panPancreatic cancerPancreatic cancer action network

Cantargia AB: Cantargia publishes preclinical data on strong anti-tumor efficacy of nadunolimab in combination with chemotherapy

LUND, Sweden, Aug. 30, 2022 /PRNewswire/ Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported publication of preclinical results demonstrating that Cantargia's lead candidate

Rydberg millrudPrnewswire cantargiaNasdaq stockholmCancer immunology

Cantargia reports new positive preclinical efficacy data for CAN10 supporting development in myocarditis

LUND, Sweden, July 25, 2022 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported.

United statesPrnewswire cantargiaJohns hopkins university school of medicineCardiovascular sciencesNasdaq stockholmJohns hopkins university schoolBasic cardiovascular sciencesScientific sessions

vimarsana © 2020. All Rights Reserved.